Efficacy, tolerability and safety of once-monthly administration of 75Â mg risedronate in Japanese patients with involutional osteoporosis: A comparison with a 2.5Â mg once-daily dosage regimen

In conclusion, risedronate 75 mg once-monthly (a dosage which is 30 times higher than risedronate 2.5 mg once-daily) had non-inferior efficacy in terms of BMD and was similarly well tolerated compared to the once-daily regimen in Japanese patients with involutional osteoporosis. Consistent with the once-daily and once-weekly dosage, the once-monthly dosage of risedronate 75 mg was half that used outside Japan (150 mg).